ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sacituzumab tirumotecan

Also written as “Sacituzumab tirumotecan”, “SKB264” and “Sacituzumab Tirumotecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms · Ovarian Neoplasms · Endometrial Neoplasms, led by 4 companies.

Drug pageSacituzumab tirumotecan: every studyAll 113 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 3, 202350 company-led studies, 48 open or runningLicense: Kelun-Biotech → MerckNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck2928 open or runningphase 3since Oct 3, 2023Apr 1, 2022May 10, 2027phase 3 · NCT06074588
Sichuan Kelun Pharmaceuticalits history only1716 open or runningphase 3since Apr 15, 2022Apr 15, 2022Nov 2026phase 3 · NCT06448312
Klus Pharmaits history only33 open or runningphase 2since Oct 29, 2019Oct 29, 2019Nov 30, 2027phase 2 · NCT05642780
Convalife (Shanghai)its history only11 open or runningphase 2since Aug 22, 2025Aug 22, 2025Aug 12, 2028phase 2 · NCT07157956
  • Named in Merck’s own pipeline as sacituzumab tirumotecan (MK-2870), phase 4, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo and Myriad Genetics.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Klus Pharma and Convalife (Shanghai) relate to it is not in the registry or these sources.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 11 earlier studies, Apr 1, 2022 to May 15, 2024.

  1. Aug 6, 2023Named sacituzumab tirumotecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, SKB264
  2. May 20, 20242 phase 2 studiesNCT06428409, NCT06445972
  3. Jun 10, 2024Phase 3 study in Uterine Cervical NeoplasmsNCT06459180 · 686 enrolled · United States, Argentina, Australia and more
  4. Jun 17, 20242 phase 2 studiesNCT06469944, NCT06483334
  5. Oct 9, 2024Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06637423 · 35 enrolled · United States, Canada, France and more
  6. Jan 13, 20252 phase 2 studiesNCT06780111, NCT06788912
  7. Feb 7, 20252 phase 3 studiesNCT06824467, NCT06841354
  8. Apr 23, 2025Phase 3 study in Endometrial NeoplasmsNCT06952504 · 1,123 planned · United States, Argentina, Australia and more
  9. May 4, 2025Phase 3 study in Breast NeoplasmsNCT06966700 · 2,400 planned · United States, Argentina, Australia and more
  10. Oct 10, 2025Phase 3 study in Uterine Cervical NeoplasmsNCT07216703 · 1,023 planned · United States, Argentina, Austria and more
  11. Nov 20, 2025Phase 2 study in NeoplasmsNCT07252739 · 140 planned · United States, Chile, China and more
  12. Jan 2, 2026Phase 3 study in Ovarian NeoplasmsNCT07318558 · 900 planned · United States, Argentina, Australia and more
  13. Feb 10, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07419295 · 590 planned · United States, Argentina, Australia and more
  14. Sep 15, 2026Phase 3 study in Urinary Bladder NeoplasmsNCT07829783 · 400 planned · Taiwan, Ukraine
  15. Oct 26, 2026Phase 2 study in Metastatic Castration-resistant Prostate CancerNCT07908524 · 290 planned

Ahead

  1. May 10, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06074588
  2. Jun 11, 2027Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaNCT05319730
  3. Jul 11, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06312176
  4. Dec 31, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06049212

TargetBeta

“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugate…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
datopotamab deruxtecanruleAstraZenecaphase 329
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 29 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908524Metastatic Castration-resistant Prostate Cancer2Not yet recruitingJun 29, 2032290
NCT07829783Urinary Bladder Neoplasms · Taiwan, Ukraine3RecruitingNov 17, 2031400
NCT07419295Urinary Bladder Neoplasms · United States, Argentina, Australia and more3RecruitingJul 27, 2029590
NCT07318558Ovarian Neoplasms · United States, Argentina, Australia and more3RecruitingFeb 25, 2033900
NCT07252739Neoplasms · United States, Chile, China and more2RecruitingNov 15, 2029140
NCT07216703Uterine Cervical Neoplasms · United States, Argentina, Austria and more3RecruitingOct 29, 20311,023
NCT06966700Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMar 23, 20332,400
NCT06952504Endometrial Neoplasms · United States, Argentina, Australia and more3RecruitingMay 24, 20321,123
NCT06841354Triple Negative Breast Neoplasms · United States, Argentina, Australia and more3RecruitingMay 18, 20301,000
NCT06824467Ovarian Neoplasms · United States, Argentina, Australia and more3RecruitingApr 27, 2029770
NCT06788912Lung Neoplasms · United States, Chile, Greece and more2Active, not recruitingFeb 6, 203260
NCT06780111Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more2RecruitingJan 4, 2032298
NCT06637423Non-Muscle Invasive Bladder Neoplasms · United States, Canada, France and more2CompletedSep 30, 202635
NCT06483334Carcinoma, Transitional Cell · United States, Canada, France and more2Active, not recruitingMar 31, 202838
NCT06469944Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingSep 12, 2029160
NCT06459180Uterine Cervical Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJun 15, 2028686
NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingMay 9, 2028210
NCT06428409Colorectal Neoplasms · United States, Australia, Canada and more2RecruitingOct 16, 2029220
NCT06422143Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3RecruitingJan 12, 2029851
NCT06393374Triple Negative Breast Neoplasms · United States, Argentina, Australia and more3RecruitingDec 16, 20301,530
NCT06356311Adenocarcinoma Of Esophagus · United States, Belgium, Brazil and more3Active, not recruitingOct 19, 2026473
NCT06312137Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingFeb 21, 2034780
NCT06312176Breast Neoplasms · United States, Argentina, Australia and more3RecruitingJul 11, 20271,200
NCT06305754Carcinoma, Non-Small-Cell Lung · United States, Argentina, Canada and more3Active, not recruitingAug 17, 2028550
NCT06170788Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingJan 25, 2028614
NCT06132958Endometrial Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJan 10, 2028710
NCT06074588Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3Active, not recruitingMay 10, 2027556
NCT06049212Carcinoma, Non-Small-Cell Lung · Japan1Active, not recruitingDec 31, 202730
NCT05319730Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more2RecruitingJun 11, 2027230

How it is read

Names in the registry

  • “Sacituzumab tirumotecan”, 22 entries
  • “SKB264”, 15 entries
  • “Sacituzumab Tirumotecan”, 5 entries
  • “SKB264+SKB118”, 2 entries
  • “sac-TMT”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.